More News! 19 Mar 2018
Could the Microbiome Treat Side Effects of Stem Cell Transplants?
MaaT Pharma, based in Lyon, has received authorization to launch a Phase II trial for its therapy, which targets the gut microbiota to treat complications from stem cell transplants. MaaT Pharma will launch a Phase II trial for MaaT013, a therapy for treating acute graft-versus-host disease — a major complication of hematopoietic stem cell transplantation […]